| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AngIII |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AngIII重组蛋白的3篇参考文献及摘要概括：
---
1. **文献名称**: *"Recombinant Angiotensin III: Expression and Cardiovascular Effects in Hypertensive Rats"*
**作者**: Li Y, Zhang H, et al.
**摘要**: 研究利用大肠杆菌系统成功表达重组AngIII，纯化后通过腹腔注射于自发性高血压大鼠。结果显示AngIII显著升高血压并激活AT1受体，提示其可能通过该受体介导升压效应。
2. **文献名称**: *"Biochemical Characterization of Human Angiotensin III Produced in HEK293 Cells"*
**作者**: Santos RA, Campagnole-Santos MJ.
**摘要**: 作者在HEK293哺乳细胞中重组表达人源AngIII，通过质谱和HPLC验证纯度及结构。体外实验证实AngIII对AT2受体的亲和力高于AT1.可能解释其部分生理功能的双相调节作用。
3. **文献名称**: *"AngIII-Mediated Oxidative Stress in Renal Tubules: Insights from Recombinant Protein Studies"*
**作者**: Suzuki Y, Kawahara T.
**摘要**: 研究利用重组AngIII处理肾小管上皮细胞，发现其通过激活NADPH氧化酶增加ROS生成，导致细胞凋亡。结果提示AngIII可能在肾脏损伤中起促氧化应激作用。
---
注：上述文献信息为基于领域知识的模拟概括，实际引用时建议通过PubMed或Web of Science核对原文。
**Background of AngIII Recombinant Protein**
Angiotensin III (AngIII) is a bioactive peptide derived from the renin-angiotensin system (RAS), a critical regulator of blood pressure, fluid balance, and electrolyte homeostasis. It is generated through enzymatic processing of angiotensin II (AngII) by aminopeptidases, which remove the N-terminal aspartic acid residue. AngIII shares functional overlap with AngII but exhibits distinct receptor-binding preferences and physiological roles, primarily mediated through interactions with angiotensin type 1 (AT1) and type 2 (AT2) receptors.
Recombinant AngIII is produced using genetic engineering techniques, often expressed in *E. coli* or mammalian cell systems to ensure high purity and biological activity. This synthetic approach allows precise control over post-translational modifications and scalability for research or therapeutic applications. The recombinant protein typically retains the native 7-amino-acid structure (Arg-Val-Tyr-Ile-His-Pro-Phe) and is validated for bioactivity through receptor-binding assays and functional studies.
Functionally, AngIII is implicated in vasoconstriction, aldosterone secretion, and central nervous system-mediated blood pressure regulation. Emerging studies highlight its role in pathophysiological conditions, including hypertension, heart failure, and renal dysfunction. Unlike AngII, AngIII may preferentially influence AT2 receptor signaling, which is associated with vasodilation and tissue protection, suggesting unique therapeutic potential.
Research applications of recombinant AngIII include elucidating RAS signaling mechanisms, drug discovery for cardiovascular diseases, and exploring its neuroprotective or detrimental effects in brain disorders. Its recombinant form provides a standardized tool for *in vitro* and *in vivo* studies, overcoming limitations of endogenous peptide instability. Ongoing investigations aim to clarify its distinct roles and leverage its properties for targeted therapies.
×
